Literature DB >> 25991594

Impact of pharmacist intervention in conjunction with outpatient physician follow-up visits after hospital discharge on readmission rate.

Matthew E Arnold1, Lucinda Buys2, Fekadu Fullas3.   

Abstract

OBJECTIVE: The Medicare Hospital Readmissions Reduction Program (MHRRP) which took effect on October 1st, 2012 holds providers accountable for quality of care delivered, placing a greater focus on care coordination. Innovative strategies in medication management in the acute care and outpatient primary care settings require vigilant pharmacist intervention. The objective of this study is to determine if pharmacist-provided medication reconciliation service in conjunction with hospital follow-up outpatient physician visits reduces hospital readmission rate.
METHODS: This was a prospective study in which physician-initiated outpatient hospital follow-up appointment scheduling was used to identify patients at time of hospital discharge. All patients ≥50 years of age were eligible for outpatient pharmacist visits. Emergency room visits were excluded. Data collected included: patient demographics, characteristics of identified drug therapy problems, accuracy of outpatient medication histories and time required by pharmacist to perform the reviews. Patient adherence to early (24-72 hours) outpatient hospital follow-up visit was also evaluated. Previous year's readmission data for high risk patients who received only physician visits were also collected for comparison with those who were jointly visited by pharmacists and physicians.
RESULTS: A total of 98 patients were assigned to receive pharmacist intervention in conjunction with physician hospital follow-up visits. Nine of the 98 patients seen by pharmacists at hospital follow-up visits were readmitted (9.2%) to a hospital within 30 days of discharge. Out of the 236 patients seen during the same period the previous year (2011) for physician alone hospital follow-up visits 46 were readmitted (19.4%) within 30-days of hospital discharge. The difference between these groups was statistically significant (p = 0.023), with patients in the pharmacist intervention group experiencing a reduction in 30-day readmission risk. Physician alone outpatient follow-up was associated with earlier mean time to readmission, 12.8 days vs. 18.3 days in the pharmacist intervention group (p = 0.042).
CONCLUSION: Pharmacist involvement in hospital discharge follow-up visits reduced overall readmission rate in high risk patients and improved monitoring of drug therapy, and medication history accuracy when compared to physician-alone visits.
Copyright © 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25991594     DOI: 10.2146/sp150011

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  14 in total

1.  Exploring the Community Pharmacist's Knowledge of Celiac Disease.

Authors:  Carmela Avena-Woods; Robert A Mangione; Wenchen Kenneth Wu
Journal:  Am J Pharm Educ       Date:  2018-03       Impact factor: 2.047

2.  Effectiveness of a multicomponent pharmacist intervention at hospital discharge for drug-related problems: A cluster randomised cross-over trial.

Authors:  Xavier Pourrat; Clémence Leyrat; Benoît Allenet; Brigitte Bouzige; Armelle Develay; Martial Fraysse; Valérie Garnier; Jean-Michel Halimi; Clarisse Roux-Marson; Bruno Giraudeau
Journal:  Br J Clin Pharmacol       Date:  2020-06-07       Impact factor: 4.335

3.  Impact of pharmacist participation in the patient care team on value-based health measures.

Authors:  Michael Patti; Evan W Colmenares; Anna Abrahamson; Sarah Weddle; Jamie Cavanaugh; Zack Deyo; Mary-Haston Vest
Journal:  Am J Health Syst Pharm       Date:  2022-09-22       Impact factor: 2.980

4.  Impact of Pharmacist Interventions on the Long-Term Clinical Outcomes in Patients with Myocardial Infarction.

Authors:  Chun-Chi Chiou; Tzu-Hsien Tsai; Chien-Ho Lee; Cheng-Jei Lin; Wen-Jung Chung; Shu-Kai Hsuch; Po-Jui Wu; Cheng-I Cheng
Journal:  Acta Cardiol Sin       Date:  2019-05       Impact factor: 2.672

5.  Comprehensive and Collaborative Pharmacist Transitions of Care Service for Underserved Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Jennifer Kim; Amy Lin; Randy Absher; Tanya Makhlouf; Casey Wells
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

6.  Readmission Rates Associated with Pharmacist Involvement in a Geriatric Transitional Care Management Clinic.

Authors:  E Jared McPhail; Vincent D Marshall; Tami L Remington; Sarah E Vordenberg
Journal:  Innov Pharm       Date:  2019-10-14

7.  Reducing Emergency Department Visits Among Patients With Diabetes by Embedding Clinical Pharmacists in the Primary Care Teams.

Authors:  Gerardo Moreno; Jeffery Y Fu; Janet S Chon; Douglas S Bell; Jonathan Grotts; Chi-Hong Tseng; Richard Maranon; Samuel S Skootsky; Carol M Mangione
Journal:  Med Care       Date:  2021-04-01       Impact factor: 3.178

8.  Roles of disease severity and post-discharge outpatient visits as predictors of hospital readmissions.

Authors:  Hao Wang; Carol Johnson; Richard D Robinson; Vicki A Nejtek; Chet D Schrader; JoAnna Leuck; Johnbosco Umejiego; Allison Trop; Kathleen A Delaney; Nestor R Zenarosa
Journal:  BMC Health Serv Res       Date:  2016-10-10       Impact factor: 2.655

9.  Reducing Medical Admissions into Hospital through Optimising Medicines (REMAIN HOME) Study: protocol for a stepped-wedge, cluster-randomised trial.

Authors:  Holly Foot; Christopher Freeman; Karla Hemming; Ian Scott; Ian D Coombes; Ian D Williams; Luke Connelly; Jennifer A Whitty; Nancy Sturman; Sue Kirsa; Caroline Nicholson; Grant Russell; Carl Kirkpatrick; Neil Cottrell
Journal:  BMJ Open       Date:  2017-04-13       Impact factor: 2.692

10.  Effect of Postdismissal Pharmacist Visits for Patients Using High-Risk Medications.

Authors:  Joseph R Herges; Lori B Herges; Ross A Dierkhising; Kristin C Mara; Amanda Z Davis; Kurt B Angstman
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.